C-BE5Eengineered cells, gene repair, cell replacement
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Evaluate SC291 in subjects with severe autoimmune diseases involving B cells.
Phase 1 clinical study evaluating safety and tolerability, preliminary clinical response, cellular kinetics, and exploratory assessments.
ClinicalTrials.gov record for SC291-102 GLEAM Phase 1 study published 2024-04-29.
Evaluate SC262 in subjects with relapsed or refractory non-Hodgkin's lymphoma.
Phase 1 clinical study evaluating safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
ClinicalTrials.gov record for SC262-101 VIVID Phase 1 study published 2024-04-18.
Evaluate SC291 in subjects with relapsed or refractory B-cell malignancies.
Phase 1 clinical study evaluating safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
ClinicalTrials.gov record for SC291-101 ARDENT Phase 1 study published 2023-05-02.
Create in vivo cell therapies by delivering genetic payloads directly to target immune or stem/progenitor cells.
Envelope-engineered virus-like particles and fusogen technologies for in vivo delivery, including in vivo CAR-T generation and in vivo gene editing of human hematopoietic stem and progenitor cells.
2025 publications listed for in vivo CAR-T cell therapy and in vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles.
Enable engineered allogeneic cells to evade immune rejection and support broadly available cell medicines, including cell replacement and CAR-T applications.
Hypoimmune engineering of cells such as induced pluripotent stem cells, pancreatic islets, and CAR-T cells to avoid rejection in immunocompetent models.
Published 2023-2025 studies showing long-term survival of hypoimmune iPSCs in rhesus macaques, insulin independence after hypoimmune islet transplantation in non-human primates, and survival of transplanted allogeneic beta cells without immunosuppression.
Supplied publications report long-term survival in immunocompetent allogeneic rhesus macaques, insulin independence after allogeneic transplantation in fully immunocompetent non-human primates, avoidance of rejection/autoimmunity in humanized mice, and survival of transplanted allogeneic beta cells without immunosuppression.
Pipeline-listed engineered cell program; supplied material does not specify the target indication or objective.
Engineered cell medicine; supplied material does not provide further method details.
Listed in Sana's supplied pipeline list.
Pipeline-listed CD8/BCMA program, consistent with Sana's work in B-cell related diseases.
CD8/BCMA engineered cell or in vivo cell-engineering approach; supplied material identifies the program label but not detailed protocol.
Listed in Sana's supplied pipeline list.
Pipeline-listed CD8/CD19 program, consistent with Sana's work in B-cell cancers or B-cell related autoimmune disorders.
CD8/CD19 engineered cell or in vivo cell-engineering approach; supplied material identifies the program label but not detailed protocol.
Listed in Sana's supplied pipeline list.
Pipeline-listed engineered cell program associated with Sana's broader focus on type 1 diabetes and cell replacement.
Engineered cell medicine; supplied material does not specify the exact intervention beyond Sana's hypoimmune/cell-replacement focus.
Listed in Sana's supplied pipeline list.